Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids.

PubWeight™: 3.55‹?› | Rank: Top 1%

🔗 View Article (PMC 2903874)

Published in Transplant Proc on October 01, 1987


S Todo1, A J Demetris, Y Ueda, O Imventarza, K Okuda, A Casavilla, S Cemaj, A Ghalab, V Mazzaferro, B S Rhoe

Author Affiliations

1: Department of Surgery, University Health Center of Pittsburgh, PA.

Articles citing this

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Kidney transplantation under FK 506. JAMA (1990) 7.45

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15

The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80

Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg (1994) 1.33

Canine total orthotopic small bowel transplantation under FK 506. Transplant Proc (1991) 1.29

Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. Transplant Proc (1990) 0.93

Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. Transplant Proc (1990) 0.91

Tacrolimus (FK506)-Associated Renal Pathology. Adv Anat Pathol (1997) 0.90

Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. Clin Exp Immunol (1990) 0.89

New approaches in the use of cyclosporine: with particular reference to the liver. Transplant Proc (1988) 0.86

Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. Transplantation (1990) 0.83

The effect of FK 506 on small intestine allotransplantation in the rat. Transplant Proc (1990) 0.79

Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. Am J Surg Pathol (1996) 0.79

Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. Immunology (1990) 0.77

Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. Clin Transpl (1994) 0.76

Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction. J Heart Lung Transplant (1997) 0.75

Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. Transplant Proc (1991) 0.75

Articles by these authors

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Isolation and characterization of acid phosphatase mutants in Saccharomyces cerevisiae. J Bacteriol (1973) 5.24

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96


Liver transplantation (1). N Engl J Med (1989) 4.53

Studies on protein folding, unfolding and fluctuations by computer simulation. I. The effect of specific amino acid sequence represented by specific inter-unit interactions. Int J Pept Protein Res (1975) 4.49

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension (2001) 4.07

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Propensity of ectopic liver to hepatocarcinogenesis: case reports and a review of the literature. Hepatology (1999) 3.29

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Cancer (1983) 3.28

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Renal transplantation in baboons under FK 506. Surgery (1989) 3.17

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med (1996) 3.13

Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11

Nonsurgical, percutaneous transhepatic cholangiography--diagnostic significance in medical problems of the liver. Am J Dig Dis (1974) 3.09

Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98

Liver transplantation (2). N Engl J Med (1989) 2.93

Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol (1996) 2.81

The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

Isolation and characterization of recessive, constitutive mutations for repressible acid phosphatase synthesis in Saccharomyces cerevisiae. J Bacteriol (1975) 2.71

A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Characterization of genes in the cellulose-synthesizing operon (acs operon) of Acetobacter xylinum: implications for cellulose crystallization. J Bacteriol (1994) 2.49

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48

NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol (1994) 2.40

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39


Haemagglutinating activity of Bacteroides melaninogenicus. Arch Oral Biol (1974) 2.35

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28

Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28

Percutaneous transhepatic drainage of the biliary tract: technique and results in 104 cases. Gastroenterology (1978) 2.27

Portal hemodynamics in patients with gastric varices. A study in 230 patients with esophageal and/or gastric varices using portal vein catheterization. Gastroenterology (1988) 2.26

Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene (1993) 2.25

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20

Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20

Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17

The long-term pathological evolution of chronic hepatitis C. Hepatology (1996) 2.15

Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology (2000) 2.15

Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography: comparison with invasive technique. J Am Coll Cardiol (1998) 2.14

Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14

Relativistic jet activity from the tidal disruption of a star by a massive black hole. Nature (2011) 2.12

Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol (1990) 2.11

Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology (1985) 2.11

One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev (2010) 2.09

Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol (1993) 1.98

Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation (1997) 1.98

Pathology of human intestinal transplantation. Gastroenterology (1996) 1.98

Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95

Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94

Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94

Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation (1999) 1.93

Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. Gastroenterology (1985) 1.92

A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol (2000) 1.92

Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89

Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology (1992) 1.85

Purification and properties of hemagglutinin from culture supernatant of Bacteroides gingivalis. Infect Immun (1986) 1.85

Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol (2006) 1.84

Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells (1995) 1.83